Loading…
Reported covered position: Rep. Earl L. Buddy Carter-Legislative Director, Senior Policy Advisor, Legislative Assistant; Rep. Jack Kingston--Intern
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 10559 - LARC Access Expansion Act Contraceptive access
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: ORGANON & CO. · Firm: ORGANON & CO.
H.R.9029 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORGANON & CO. via ORGANON & CO.
2026 · third_quarter · Q3
One Big Beautiful Bill Act (P.L. 119-21) - provisions related to Medicaid coverage, rural health funding, and drug pricing. Drug pricing, women's health, biosimilars.
FY27 appropriations
Source: Senate LDA
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Great Basin National Heritage Area and Mormon Pioneer National Heritage Area Extension Act
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Water Affordability, Transparency, Equity, and Reliability Act of 2021
Client: ORGANON & CO. · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: ORGANON & CO. · Firm: ORGANON & CO.
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
H.R. 10559 - LARC Access Expansion Act Contraceptive access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2026 · second_quarter · Q2
FY27 appropriations.
Drug pricing Women's health Biosimilars One Big Beautiful Bill Act (Public Law 119-21)--provisions related to Medicaid coverage, rural health funding, and drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2026 · first_quarter · Q1
FY27 appropriations.
Drug pricing Women's health Biosimilars One Big Beautiful Bill Act (Public Law 119-21)--provisions related to Medicaid coverage, rural health funding, and drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2025 · fourth_quarter · Q4
Drug pricing Women's health Biosimilars One Big Beautiful Bill Act (PL 119-21)--provisions related to Medicaid coverage, rural health funding, and drug pricing
FY26 appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2025 · third_quarter · Q3
Drug pricing Women's health Biosimilars One Big Beautiful Bill Act (PL 119-21)--provisions related to Medicaid coverage, rural health funding, and drug pricing
FY26 appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2025 · second_quarter · Q2
Drug pricing Women's health Biosimilars One Big Beautiful Bill Act (PL 119-21)--provisions related to Medicaid coverage, rural health funding, and drug pricing
FY26 appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2025 · first_quarter · Q1
Drug pricing Women's health Biosimilars
FY25 appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2024 · fourth_quarter · Q4
FY25 appropriations
Drug Pricing Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2024 · third_quarter · Q3
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
FY25 appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2024 · second_quarter · Q2
H.R.9029 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2024 · first_quarter · Q1
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, White House Office
ORGANON & CO. via ORGANON & CO.
2023 · fourth_quarter · Q4
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · third_quarter · Q3
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · second_quarter · Q2
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2023 · first_quarter · Q1
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · fourth_quarter · Q4
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · third_quarter · Q3
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · second_quarter · Q2
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2022 · first_quarter · Q1
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via ORGANON & CO.
2021 · fourth_quarter · 4A
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORGANON & CO. via ORGANON & CO.
2021 · fourth_quarter · Q4
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Issues related to Medicare reimbursement for biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORGANON & CO. via ORGANON & CO.
2021 · third_quarter · Q3
S. 1427/HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act Executive Order Promoting Competition in the American Economy--Blended J-codes for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE